L.GershB
Cai X, She M, Xu M, Chen H, Li J, Chen X, Zheng D, Liu J, Chen S, Zhu J
They also endorse the conclusion of both the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society: Patients who develop NAION while on GLP-1 drugs should engage in a shared decision-making process with their physicians, including their ophthalmologist, neurologist, primary care physician, or endocrinologist
Use in type 1 diabetes The ADJUNCT ONE trial (Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes), 55 the ADJUNCT TWO trial, 56 and a large meta-analysis 57 found reductions in hemoglobin A1c, body weight, and total daily dose of insulin, but also highlighted an increase in hyperglycemia with ketosis in patients with type 1 diabetes mellitus receiving liraglutide or exenatide in combination with insulin
doi: 10.1111/hel.12796 39 GrasbergerHEl-ZaatariMDangDTMerchantJL